CompanyALDXNasdaqLexington, MA

Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics develops RASP modulators including reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation for vitreoretinal lymphoma and retinitis pigmentosa.

Stories only

SEC EDGAR ClinicalTrials.gov aldeyra.com

8-KSep 29Latest SEC filing

Jul 30Latest story

July 2026

Aldeyra Therapeutics signs new lease for Concord, Massachusetts headquarters

Jul 30PartnershipAldeyra Therapeutics, Inc.